Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide in Overweight and Very Overweight Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have stable body weight for the past 1 month prior to screening~* Have a body mass index (BMI) between 27 to 50 kilograms per meter squared (kg/m²), inclusive at screening~* Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff~* Women must not be pregnant or breastfeeding~Exclusion Criteria:~* Have undergone or plan to undergo gastric bypass or bariatric surgery~* Have claustrophobia or have ferromagnetic implants that can interfere with completion of fMRI measurements~* Have other medical conditions or medical history that make participation in the study unsafe or which may interfere in the interpretation of the results of the study~* Unwilling to comply with smoking and alcohol restrictions during the study~* Have received prescription drugs or over the counter drugs that promote weight loss in the past 6 months prior to screening~* Have a diagnosis of type 2 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tirzepatide (Type: EXPERIMENTAL): Participants received tirzepatide 5 milligrams (mg) once a week (QW) for Weeks 1 through 3 followed by tirzepatide 10 mg QW for Weeks 4 through 6 into the subcutaneous (SC) tissue of the abdominal wall.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered into the SC tissue of the abdominal wall.
- Liraglutide (Type: ACTIVE_COMPARATOR): Participants received Liraglutide with step wise dose escalation regimen starting from 0.6 mg once daily (QD) for week 1 followed by 1.2 mg QD for week 2, 1.8 mg QD for week 3, 2.4 mg QD for Week 4 followed by 3 mg QD starting in Week 5 and maintained for 10 days administered into the SC tissue of the abdominal wall.

Based on this trial design, predict the completion outcome and termination type (if applicable).